甾醇调节元件结合蛋白
蛋白激酶B
癌症研究
蛋白激酶A
生物
化学
磷酸烯醇丙酮酸羧激酶
激酶
生物化学
信号转导
甾醇
酶
胆固醇
作者
Fei Shao,Xueli Bian,Hongfei Jiang,Gaoxiang Zhao,Lei Zhu,Daqian Xu,Shuai Wang,Wei Guo,Dongming Xing,Qi Xue,Yibo Gao,Jie He,Zhimin Lu
标识
DOI:10.1016/j.ejca.2020.09.040
摘要
Background Metabolic enzymes have non-canonical functions and play vital roles in the regulation of various cellular activities. Phosphoenolpyruvate carboxykinase 1 (PCK1), a gluconeogenic enzyme, was recently identified as an AKT-dependent protein kinase and promoted sterol regulatory element-binding protein 1 (SREBP1)–dependent lipogenesis. However, association of this protein kinase activity of PCK1 with progression of oesophageal squamous cell carcinoma (ESCC) is unclear. Methods We examined 200 ESCC patient samples and prognosis using immunohistochemistry, multivariate Cox regression and Kaplan–Meier Plot analyses. Results We show that the expression levels of AKT pS473, AKT-regulated PCK1 pS90, PCK1-mediated INSIG1 pS207/INSIG2 pS151 and nuclear SREBP1 were higher in analysed 200 human ESCC specimens than in their adjacent non-tumour tissues; the expression levels of these proteins were significantly and positively correlated with each other in tumour specimens. In addition, the expression levels of PCK1 pS90, INSIG1 pS207/INSIG2 pS151 and SREBP1 were associated with the tumour, node and metastasis stage and progression in ESCC. Importantly, levels of PCK1 pS90 or INSIG1 pS207/INSIG2 pS151 or nuclear SREBP1 were positively correlated with poor prognosis in patients with ESCC, and the combined expression values of PCK1 pS90, INSIG1 pS207/INSIG2 pS151 and nuclear SREBP1 had a better prognostic value than that of each individual protein expression value and was an independent prognostic marker for ESCC. Conclusion These findings reveal the role of PCK1 protein kinase activity-dependent SREBP1 activation in ESCC progression. The regulation of SREBP1 by AKT activation-dependent PCK1 protein kinase activity may provide the potential for the diagnosis and treatment of human ESCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI